Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis

BACKGROUND: The evidence for benefits of bivalirudin over heparin has recently been challenged. We aimed to analyse the safety and cost-effectiveness following reintroduction of heparin instead of bivalirudin as the standard anticoagulation for primary percutaneous coronary intervention (PPCI) in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Deharo, Pierre, Johnson, Thomas W, Rahbi, Hazim, Kandan, Raveen, Bowles, Ruth, Mozid, Abdul, Dorman, Stephen, Strange, Julian W, Baumbach, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Interventional Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950626/
https://www.ncbi.nlm.nih.gov/pubmed/29765614
http://dx.doi.org/10.1136/openhrt-2017-000767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950626/
https://www.ncbi.nlm.nih.gov/pubmed/29765614
http://dx.doi.org/10.1136/openhrt-2017-000767

Ejemplares similares